



**Department of Vermont Health Access
Pharmacy Benefits Management Program
*DUR Board Meeting Agenda***

October 19, 2021: 5:00 – 8:30 p.m.

- **Executive Session** **5:00 - 6:00**

- **Introductions and Approval of DUR Board Minutes** **6:00 - 6:05**
(Public Comment Prior to Board Action)

- **DVHA Pharmacy Administration Updates** **6:05 - 6:10**

- **Medical Director Update** **6:10 - 6:15**

- **Proposed 2022 DURB Meeting Schedule** **6:15- 6:20**

- **Follow-up Items from Previous Meetings** **6:20 - 6:25**
 - Codeine Use in Pediatrics

- **RetroDUR/ProDUR** **6:20- 6:45**
 - Introduce: Discussion Topics for 2022 RetroDUR Initiatives
 - Introduce: Immunologic Therapies for Asthma

- **Clinical Update: Drug Reviews** **6:45-6:45**
(Public comment prior to Board action)
 - **Biosimilar Drug Reviews**
 - None at this time.

 - **Full New Drug Reviews**
(Any new drug reviews that also fall within the Therapeutic Class Review (TCR) will be discussed during the Therapeutic Class Review)
 - None at this time

- **New Managed Therapeutic Drug Classes** **6:45 -6:45**
(Public comment prior to Board action)
 - None at this time

- **Therapeutic Drug Classes – Periodic Review** **6:45 – 6:45**
(Public comment prior to Board action)
 - None at this time

- **Review of Newly Developed/Revised Criteria** **6:45 – 8:20**
(Public comment prior to Board action)
 - (All changes will be effective January 1, 2021)
 - ADHD/Short Acting Stimulants
 - ADHD/Long Acting Stimulants
 - ADHD/Miscellaneous

- Alzheimer's
 - Anticoagulants/Oral
 - Anticonvulsants/Oral
 - Antidiabetics/GLP-1 RA
 - Antidiabetics/ Insulin Long-acting
 - Antiretrovirals
 - Atopic Dermatitis
 - Cardiovascular/Beta Blockers
 - Cardiovascular/PCSK9 Inhibitors
 - Cystic Fibrosis/Inhaled Antibiotics
 - Cytokine Modulators (includes the following PDL classes):
 - Ankylosing Spondylitis Injectables
 - Gastrointestinal Inflammatory Disease Biologics
 - Psoriasis
 - Rheumatoid, Juvenile, and Psoriatic Arthritis Immunomodulators
 - Hematopoietics/Colony Stimulating Factors
 - Hemophilia/Factor VIII
 - Hemophilia/Factor IX
 - Immunologic Therapies for Asthma
 - Migraine Therapy/Acute Treatments (Gepants only)
 - Migraine Therapy/Preventative Treatment
- **General Announcements** **8:20 – 8:30**
- Clozapine Risk Evaluation and Mitigation Strategy (REMS) requirements will change on November 15, 2021
https://www.fda.gov/drugs/drug-safety-and-availability/clozapine-risk-evaluation-and-mitigation-strategy-rems-requirements-will-change-november-15-2021?utm_medium=email&utm_source=govdelivery
- Three JAK Inhibitors Get Boxed Warnings, Modified Indications
https://www.medscape.com/viewarticle/958024?src=wnl_newsalert_210901_MSCPEDIT&uac=2185FK&impID=3609579&faf=1
- **Adjourn** **8:30**